Original Article
Effect of Payor-Mandated Review of Prescription Drug Monitoring Program on Opioid Prescriber Rates
Abstract
Objective: To evaluate the effect of a 2016 South Carolina payor mandate to query the state prescription drug monitoring program (PDMP) before prescribing controlled substances on the rate of opioid prescribers in South Carolina.Methods: South Carolina PDMP datasets from 2010–2017 were evaluated using interrupted time series regression to compare changes in the rate of opioid prescribers before and after the 2016 mandate. The rate of opioid prescribers was defined as the number of prescribers who prescribed class II to IV opioids on any one prescription in each quarter divided by the total number of South Carolina prescribers who prescribed any one class II to IV medication. The rate of high-dose opioid prescribers was defined as the number of prescribers who prescribed ≥90-morphine milligram equivalent per day on any one prescription in each quarter divided by all of the prescribers who prescribed an opioid analgesic prescription.
Results: The rates of South Carolina opioid prescribers decreased from 75% in 2010 to 60% in 2017, with no significant change in slope (P = 0.24) after the 2016 payor mandates. The rates of South Carolina high-dose opioid prescribers decreased from 40% in 2010 to 32% in 2017, with a significant decrease in slope (P < 0.001) after the payor mandate.
Conclusions: The slope of the South Carolina high-dose opioid prescriber rate significantly decreased after the 2016 South Carolina payor mandate, while the slope of the South Carolina opioid prescriber rate did not. The long-term outcomes related to the change in opioid prescriber rates are unknown and warrant further study.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. South Carolina Department of Health and Environmental Control. Drug overdose deaths: South Carolina. https://scdhec.gov/sites/default/files/media/document/Drug%20Overdose%20Deaths%20-%20South%20Carolina%202017.pdf. Published 2017. Accessed July 16, 2019.
2. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132:95-100.
3. Soura CL. Required use of the South Carolina Reporting & Identification Prescription Tracking System (SCRIPTS). https://www.scdhhs.gov/press-release/required-use-south-carolina-reporting-identification-prescription-tracking-system#:~:text=Beginning%20with%20dates%20of%20service. Published February 23, 2016. Accessed July 6, 2020.
4. Dowell D, , Haegerich TM, , Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:1-49.
5. Zhu W, Chernew ME, Sherry TB, et al. Initial opioid prescriptions among U.S. commercially insured patients, 2012-2017. N Engl J Med 2019;380:1043-1052.
6. Throckmorton D. FDA statement: statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA’ Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids. https://www.fda.gov/news-events/press-announcements/statement-douglas-throckmorton-md-deputy-center-director-regulatory-programs-fdas-center-drug-0. Published April 9, 2019. Accessed July 6, 2020.
